Digital Ally Partners with Redwood Scientific to Launch Anti-Vaping Product TBX Vape-Free.
PorAinvest
lunes, 23 de junio de 2025, 8:32 am ET1 min de lectura
DGLY--
Digital Ally, Inc. (NASDAQ: DGLY) has signed an exclusive global Master Distribution Agreement with Redwood Scientific Technologies, granting the company exclusive rights to distribute Redwood's nicotine cessation products, including TBX-Free and TBX Vape-Free. The agreement aims to help Americans overcome addiction to vape devices and traditional cigarettes, addressing a significant health crisis in the United States.
TBX-Free is designed to assist cigarette smokers in overcoming nicotine addiction, while TBX Vape-Free is a pioneering oral thin-film solution specifically targeting vape-related nicotine dependency. The agreement grants Digital Ally exclusive rights to Redwood's technologies, brands, trademarks, and manufacturing processes. According to the CDC, approximately 28.8 million U.S. adults are current cigarette smokers, and 4.5% of adults aged 18 and over report current e-cigarette use [1].
The partnership represents a strategic pivot for Digital Ally into the healthcare technology space. The company plans to launch full-scale distribution following the completion of Redwood's final-stage clinical trial. No sales or marketing will begin until the clinical study concludes, making this a pre-revenue development for now. However, the potential market for these products is substantial, with the CDC reporting 4.5% of U.S. adults currently using e-cigarettes alongside 28.8 million cigarette smokers [2].
Digital Ally's exclusive distribution agreement with Redwood Scientific highlights the company's diversification strategy and could transform its revenue model and market positioning. The tobacco cessation market has historically offered high margins, and securing exclusive distribution rights to an innovative, first-of-its-kind product could create substantial value if clinical trials demonstrate efficacy. The timing aligns with increasing regulatory scrutiny on vaping products, potentially accelerating market adoption once available.
References:
[1] https://www.stocktitan.net/news/DGLY/digital-ally-signs-exclusive-master-distribution-deal-with-redwood-xe5iclw3haxd.html
[2] https://www.globenewswire.com/news-release/2025/06/23/3103399/10618/en/Digital-Ally-Signs-Exclusive-Master-Distribution-Deal-with-Redwood-Scientific-to-Launch-Breakthrough-Anti-Vaping-Product.html
RWT--
Digital Ally has signed an exclusive global distribution deal with Redwood Scientific Technologies for Redwood's nicotine cessation products, including TBX-Free and TBX Vape-Free. The products aim to help Americans overcome addiction to vape devices. Digital Ally will have exclusive rights to distribute Redwood's technologies, brands, and manufacturing processes globally. The deal could reshape how the US approaches nicotine addiction, pending successful clinical trials.
Title: Digital Ally Secures Exclusive Global Distribution Rights for Redwood Scientific's Nicotine Cessation ProductsDigital Ally, Inc. (NASDAQ: DGLY) has signed an exclusive global Master Distribution Agreement with Redwood Scientific Technologies, granting the company exclusive rights to distribute Redwood's nicotine cessation products, including TBX-Free and TBX Vape-Free. The agreement aims to help Americans overcome addiction to vape devices and traditional cigarettes, addressing a significant health crisis in the United States.
TBX-Free is designed to assist cigarette smokers in overcoming nicotine addiction, while TBX Vape-Free is a pioneering oral thin-film solution specifically targeting vape-related nicotine dependency. The agreement grants Digital Ally exclusive rights to Redwood's technologies, brands, trademarks, and manufacturing processes. According to the CDC, approximately 28.8 million U.S. adults are current cigarette smokers, and 4.5% of adults aged 18 and over report current e-cigarette use [1].
The partnership represents a strategic pivot for Digital Ally into the healthcare technology space. The company plans to launch full-scale distribution following the completion of Redwood's final-stage clinical trial. No sales or marketing will begin until the clinical study concludes, making this a pre-revenue development for now. However, the potential market for these products is substantial, with the CDC reporting 4.5% of U.S. adults currently using e-cigarettes alongside 28.8 million cigarette smokers [2].
Digital Ally's exclusive distribution agreement with Redwood Scientific highlights the company's diversification strategy and could transform its revenue model and market positioning. The tobacco cessation market has historically offered high margins, and securing exclusive distribution rights to an innovative, first-of-its-kind product could create substantial value if clinical trials demonstrate efficacy. The timing aligns with increasing regulatory scrutiny on vaping products, potentially accelerating market adoption once available.
References:
[1] https://www.stocktitan.net/news/DGLY/digital-ally-signs-exclusive-master-distribution-deal-with-redwood-xe5iclw3haxd.html
[2] https://www.globenewswire.com/news-release/2025/06/23/3103399/10618/en/Digital-Ally-Signs-Exclusive-Master-Distribution-Deal-with-Redwood-Scientific-to-Launch-Breakthrough-Anti-Vaping-Product.html

Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios